Blueprint Medicines Corporation

BPMC

Held by 10 specialist biotech funds

High Convergence

10 funds opened new positions. Next phase2 readout (BLU-808): Dec 2026.

BiotechnologyCEO: Kathryn HavilandIPO: 2015Website ↗

Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.

Recent News & Research

PubMed

Predicting the clinical course of advanced systemic mastocytosis on treatment with avapritinib or midostaurin.

# Blueprint Medicines (BPMC) Investment Summary **Clinical Relevance:** This study provides predictive biomarkers for treatment response to avapritinib (Blueprint's flagship therapy) and midostaurin in advanced systemic mastocytosis, potentially enabling patient stratification and improved clinical outcomes that could support label expansions or real-world efficacy claims. **Commercial Implications:** Validated predictors of clinical course could strengthen avapritinib's competitive positioning against midostaurin, reduce treatment failure rates, and support premium pricing or broader reimbursement arguments, though the predictive utility and patient population size remain key variables for revenue impact. **Why it matters:** For a company heavily dependent on avapritinib revenues, evidence of superior or predictable efficacy compared to the standard-of-care midostaurin directly supports market share defense and potential label expansion in advanced systemic mastocytosis.

Oct 9, 2026

PubMed

Comment on "Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study".

# Blueprint Medicines (BPMC) - Research Summary **Clinical Finding:** This commentary discusses avapritinib's efficacy in improving cutaneous manifestations of indolent systemic mastocytosis (ISM), based on data from the Phase 2 PIONEER trial, suggesting the drug addresses visible symptoms that significantly impact patient quality of life. **Investment Implication:** The demonstration of cutaneous symptom improvement expands avapritinib's addressable market within mastocytosis by validating efficacy in a patient population that may have been underserved, potentially supporting label expansion or improved market penetration in the ISM indication beyond advanced systemic mastocytosis where the drug is already approved. **Note:** This commentary references 2026 data; verification against current FDA approval status and clinical trial timelines would be necessary for current investment analysis.

Oct 1, 2026

PubMed

Reversal of systemic mastocytosis-induced liver cirrhosis with avapritinib treatment: case report.

# Investment Summary: BPMC Avapritinib Case Report This case report documents reversal of advanced liver cirrhosis in a systemic mastocytosis patient treated with avapritinib (BPMC's KIT inhibitor), suggesting the drug may halt or reverse organ damage in severe disease—a clinically meaningful outcome beyond symptom management. If reproducible in controlled trials, this could expand avapritinib's addressable market in advanced mastocytosis and potentially support label expansion or premium pricing. However, investors should note this is a single case report; clinical validation would require prospective data to substantiate disease reversal claims and impact commercial trajectory.

Sep 6, 2026

PubMed

Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.

# BPMC Investment Summary Blueprint's avapritinib demonstrated efficacy in reducing cutaneous symptoms in indolent systemic mastocytosis (ISM) patients, expanding the drug's addressable population beyond advanced systemic mastocytosis where it already has FDA approval. This phase 2 data supports a potential label expansion or new indication in the larger, slower-progressing ISM patient segment, which could materially increase peak sales penetration in the mastocytosis market. The randomized, controlled design strengthens the evidence base for regulatory discussions and clinical adoption in dermatology-focused treatment algorithms.

Jun 1, 2026

bioRxiv

Kinetic Fingerprints as Mechanistic and Clinical Roadmaps Across KIT Activation States

# Summary for BPMC Investment Analysis This preprint describes kinetic profiling methodology for KIT receptor activation states, which is directly relevant to Blueprint's gastrointestinal stromal tumor (GIST) pipeline where KIT mutations drive disease. Understanding how different KIT mutations respond to kinase inhibitors at the molecular level could inform patient stratification, guide optimal dosing, and potentially identify resistance mechanisms—translating to improved clinical trial outcomes and market differentiation for Blueprint's KIT-targeted programs. **Investment significance:** Better mechanistic understanding of KIT biology may strengthen Blueprint's clinical positioning in GIST and support broader applications across KIT-driven malignancies, though the ultimate value depends on whether these kinetic insights translate into measurable clinical advantages in ongoing or planned trials.

May 21, 2026

Blueprint Medicines Corporation

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Catalysts

Activist Filings

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research